Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BHV3000-202: Phase 2: A Double-Blind, Placebo Controlled, Crossover Trial of BHV-3000 (Rimegepant) for Treatment Refractory Trigeminal Neuralgia

NCT03941834 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT03941834
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03941834 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BHV3000-202: Phase 2: A Double-Blind, Placebo Controlled, Crossover Trial of BHV-3000 (Rimegepant) for Treatment Refractory Trigeminal Neuralgia
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Terminated
Start date
June 25, 2019
Completion date
May 11, 2023
Enrollment
65 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

trigeminal neuralgia